US 12,239,642 B2
Bupropion dosage forms with reduced food and alcohol dosing effects
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Feb. 28, 2024, as Appl. No. 18/590,452.
Application 18/590,452 is a continuation of application No. 18/333,785, filed on Jun. 13, 2023.
Application 18/333,785 is a continuation of application No. 18/157,393, filed on Jan. 20, 2023, granted, now 11,717,518, issued on Aug. 8, 2023.
Claims priority of provisional application 63/370,771, filed on Aug. 8, 2022.
Claims priority of provisional application 63/370,590, filed on Aug. 5, 2022.
Claims priority of provisional application 63/357,521, filed on Jun. 30, 2022.
Prior Publication US 2024/0197720 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/485 (2006.01); A61K 9/20 (2006.01); A61K 31/138 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2086 (2013.01); A61K 31/138 (2013.01)] 22 Claims
 
1. A method of treating agitation associated with Alzheimer's disease, comprising: 1) selecting a human patient having agitation associated with Alzheimer's disease who is consuming alcohol; 2) administering a dosage form twice a day to the human patient to treat the agitation associated with Alzheimer's disease; and 3) advising the human patient to minimize, but not abruptly discontinue, alcohol consumption;
wherein the dosage form comprises 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and a polymer; and
wherein the human patient minimizes, but does not abruptly discontinue, alcohol consumption.